PD-L1
腺癌
细胞毒性T细胞
免疫系统
免疫检查点
癌症研究
医学
免疫组织化学
淋巴细胞
肿瘤浸润淋巴细胞
免疫疗法
免疫学
病理
癌症
生物
内科学
体外
生物化学
作者
Hans Schlößer,Uta Drebber,Michael Kloth,Martin Thelen,Sacha I. Rothschild,Simon Haase,María A. García-Márquez,Kerstin Wennhold,Felix Berlth,Alexander Urbanski,Hakan Alakus,Astrid Schauß,Alexander Shimabukuro‐Vornhagen,Sebastian Theurich,Ute Warnecke-Ebertz,Dirk L. Stippel,Alfred Zippelius,Reinhard Büttner,Michael Hallek,Arnulf H. Hölscher
出处
期刊:OncoImmunology
[Landes Bioscience]
日期:2015-11-09
卷期号:5 (5): e1100789-e1100789
被引量:56
标识
DOI:10.1080/2162402x.2015.1100789
摘要
Remarkable efficacy of immune checkpoint inhibition has been reported for several types of solid tumors and early studies in gastric adenocarcinoma are promising. A detailed knowledge about the natural biology of immune checkpoints in gastric adenocarcinoma is essential for clinical and translational evaluation of these drugs. This study is a comprehensive analysis of cytotoxic T lymphocyte associated molecule 4 (CTLA-4) and programmed death 1 ligand 1 (PD-L1) expression in gastric adenocarcinoma. PD-L1 and CTLA-4 were stained on tumor sections of 127 Caucasian patients with gastric adenocarcinoma by immunohistochemistry (IHC) and somatic mutation profiling was performed using targeted next-generation sequencing. Expression of PD-L1 and CTLA-4 on lymphocytes in tumor sections, tumor-draining lymph nodes (TDLN) and peripheral blood were studied by flow-cytometry and immune-fluorescence microscopy in an additional cohort. PD-L1 and CTLA-4 were expressed in 44.9% (57/127) and 86.6% (110/127) of the analyzed gastric adenocarcinoma samples, respectively. Positive tumor cell staining for PD-L1 or CTLA-4 was associated with inferior overall survival. Somatic mutational analysis did not reveal a correlation to expression of PD-L1 or CTLA-4 on tumor cells. Expression of PD-1 (52.2%), PD-L1 (42.2%) and CTLA-4 (1.6%) on tumor infiltrating T cells was significantly elevated compared to peripheral blood. Of note, PD-1 and PD-L1 were expressed far higher by tumor-infiltrating lymphocytes than CTLA-4. In conclusion, specific immune checkpoint-inhibitors should be evaluated in this disease and the combination with molecular targeted therapies might be of benefit. An extensive immune monitoring should accompany these studies to better understand their mode of action in the tumor microenvironment.
科研通智能强力驱动
Strongly Powered by AbleSci AI